Technology
AstraZeneca, AI biologics firm Absci tie up on cancer drug
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with US artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, Absci said in a statement on Sunday.
Absci's collaboration with AstraZeneca aims for a zero-shot generative AI model designed to create new and improved antibody therapeutics, the company said. It did not say what kind of cancer they plan to target.
Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.
"We're proud to work closely with AstraZeneca to leverage our AI to bring novel treatments to oncology patients," Absci CEO Sean McClain said.
AstraZeneca did not immediately respond to a Reuters requests for comment.
The Financial Times, which first reported the deal, said it includes an upfront fee for Absci, research and development funding and milestone payments, and royalties on any product sales.
-
Technology9h ago
Sending 'touch' over the internet could soon be as easy as sending a video with new haptic file format
-
Technology11h ago
Vaccines tell a success story that Robert F. Kennedy Jr. and Trump forget – here are some key reminders
-
Technology13h ago
Indian shares rebound led by IT sector after five-session decline
-
Technology13h ago
FAA clears SpaceX's Falcon 9 for space return
-
Technology19h ago
Reason behind social media slowdown in Pakistan revealed
-
Technology19h ago
Chinese scientists detect universe's highest energy gamma-ray line
-
Technology1d ago
AI to replace 85 million jobs by 2025: WEF report
-
Technology1d ago
Historic Russian Kremlins: Preserving heritage through architecture